<DOC>
	<DOCNO>NCT01165502</DOCNO>
	<brief_summary>The primary objective ass safety tolerability GLP-1 peptide analogue CM3.1-AC100 repeat subcutaneous ( sc ) dose .</brief_summary>
	<brief_title>Clinical Study Investigate Safety Tolerability Pharmacokinetics Multiple Ascending Doses CM3.1-AC100 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Provision sign date informed consent prior study specific procedure ; Male volunteer age 18 50 year Screening , inclusive ; Body weight 60.0 100.0 kg ( inclusive ) BMI 19 29.9 kg/m2 ( inclusive ) Any history presence clinically relevant disease judge relevant Investigator : cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , haematological , neurologic , psychiatric , systemic , ocular infectious disease acute infectious disease sign acute illness ; Blood donation within 3 month administration IP ; Presence history drug allergy , allergic disease diagnose treated physician</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>MAD study CM3.1-AC100</keyword>
	<keyword>Healthy men , age 18 - 50</keyword>
</DOC>